SATB1是癌症治疗的一个新型分子靶点。
SATB1 is a Novel Molecular Target for Cancer Therapy.
作者信息
Ding Meng, Pan Jun, Guo Zhicheng, Liu Quhe, Yang Chunhua, Mao Lijun
机构信息
a Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou University , Xuzhou , China.
b Department of Urinary Surgery , The Affiliated Hospital of University Medical College , Xuzhou , China.
出版信息
Cancer Invest. 2018 Jan 2;36(1):28-36. doi: 10.1080/07357907.2018.1423688. Epub 2018 Jan 30.
The special AT-rich sequence binding-protein1 (SATB1) attracts excessive attention due to its high expression in a variety of malignancies. SATB1 reprograms chromatin and transcription profiles to promote tumor cell growth and invasion and inhibit apoptosis, leading to tumor progression and metastasis. Consistently, silencing SATB1 with small interfering RNA inhibits the growth and invasion of some kinds of tumors. In this review, we highlight recent progress in our understanding of the role of SATB1 as global regulator of gene expression during cancer development, and evaluate the potential of SATB1 as a molecular therapeutic target for cancers with aberrant SATB1 expression.
富含AT序列结合蛋白1（SATB1）因其在多种恶性肿瘤中的高表达而备受关注。SATB1对染色质和转录谱进行重编程，以促进肿瘤细胞生长和侵袭并抑制细胞凋亡，从而导致肿瘤进展和转移。同样，用小干扰RNA沉默SATB1可抑制某些肿瘤的生长和侵袭。在本综述中，我们重点介绍了在理解SATB1作为癌症发展过程中基因表达的全局调节因子的作用方面的最新进展，并评估了SATB1作为SATB1表达异常的癌症的分子治疗靶点的潜力。
Zotero 插件